Wednesday, 17 May 2017

Summit Therapeutics PLC to receive US$22mln milestone payment as final patient enrols for DMD trial

Summit Therapeutics PLC to receive US$22mln milestone payment as final patient enrols for DMD trial: "Summit Therapeutics PLC (NASDAQ:SMMT LON:SUMM) will receive a US$22mln milestone payment from Sarepta Therapeutics (NASDAQ:SRPT) after the final patient was enrolled in a dosing trial of utrophin modulator, ezutromid.

Summit hopes the trial will identify utrophin modulation as a potential disease-modifying treatment for all patients suffering Duchenne Muscular Dystrophy (DMD),  a progressive and fatal muscle wasting disease that affects 50,000 boys and young men globally."



'via Blog this'

No comments:

Post a comment